论文部分内容阅读
目的观察普通干扰素α-1b对不同基因分型慢性丙型肝炎治疗的临床疗效。方法慢性丙型肝炎40例,根据血清基因型检测结果分1b型(24例)和2a型(16例)两组(两组性别、年龄、体质量指数(BMI)指数差异无统计学意义(P>0.05)),均应用普通干扰素α-1b 500万U,第1个月1次/d皮下注射,后隔日1次皮下注射,全程联合利巴韦林依体重不同给药800~1000 mg/d。观察12、24周疗效。结果基因1 b型组12周时ALT14例恢复正常。HCV-RNA8例阴转(<103 IU/ml),3例下降≥2 log;治疗24周时谷丙转氨酶(ALT)20例正常,HCV-RNA10例阴转,5例下降≥2 log。基因2a型组治疗12周时ALT14例恢复正常。HCV-RNA11例阴转,4例下降≥2 log,治疗24周时ALT16例正常,HCVRNA13例阴转,2例下降≥2 log。结论慢性丙型肝炎对普通干扰素α-1b联合利巴韦林抗病毒治疗12、24周时其HCV-RNA阴转率基因2a型均显著高于基因1b型(P<0.05)。
Objective To observe the clinical efficacy of common interferon α-1b in the treatment of chronic hepatitis C patients with different genotypes. Methods Forty patients with chronic hepatitis C were divided into two groups according to their genotypes: type 1b (24 cases) and type 2a (16 cases). There was no significant difference in gender, age and body mass index (BMI) between the two groups P <0.05)), were used ordinary interferon α-1b 500 million U, the first month 1 times / d subcutaneous injection, 1 subcutaneous injection the next day, the whole combined ribavirin by different body weight administered 800 to 1000 mg / d. Observation of 12,24 weeks of efficacy. Results The ALT14 cases returned to normal at 12 weeks in gene 1 b group. HCV-RNA was negative in 8 cases (<103 IU / ml) and 3 cases was decreased by ≥2 log in 24 cases. ALT was normal in 20 cases and negative in HCV-RNA in 10 cases. In the genotype 2a group, ALT14 returned to normal after 12 weeks of treatment. 11 cases of HCV-RNA were overcast, 4 cases were decreased ≥2 log, ALT16 cases were normal at 24 weeks, 13 cases of HCV RNA were negative, and 2 cases were decreased ≥2 log. Conclusion HCV-RNA negative rate gene 2a genotype 2a was significantly higher than that of genotype 1b at 12 and 24 weeks of IFN-α-1b combined with ribavirin treatment (P <0.05).